CFTR

CFTR製品

• All (18)
• CFTR阻害剤 (6)
• CFTR活性剤(3)
• CFTRモジュレータ(8)
• 新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例	お客様のフィードバック
S1144	Ivacaftor (VX-770)	Ivacaftor (VX-770) is a selective potentiator of CFTR targeting G551D-CFTR and F508del-CFTR with EC50 of 100 nM and 25 nM in fisher rat thyroid cells, respectively.	JCI Insight, 2024, 9(15)e174888 Eur J Cell Biol, 2024, 103(2):151416 Int J Mol Sci, 2024, 25(5)2770
S1565	Lumacaftor (VX-809)	Lumacaftor (VX-809, VRT 826809) acts to correct CFTR mutations common in cystic fibrosis by increasing mutant CFTR (F508del-CFTR) maturation,EC50 of 0.1 μM in fisher rat thyroid cells. Phase 3.	Cells, 2024, 13(2)185 Int J Mol Sci, 2024, 25(5)2770 Eur J Pharmacol, 2024, 967:176390
S7059	Tezacaftor (VX-661)	Tezacaftor (VX-661) is a second F508del CFTR corrector and is believed to help CFTR protein reach the cell surface. Phase 2.	Eur J Cell Biol, 2024, 103(2):151416 Front Pharmacol, 2024, 15:1370676 Int J Mol Sci, 2024, 25(5)2770
S8851	Elexacaftor (VX-445)	Elexacaftor (VX-445) is a next-generation cystic fibrosis transmembrane conductance regulator (CFTR) corrector.This is a compound which is not chiral purity.	Eur J Cell Biol, 2024, 103(2):151416 Front Pharmacol, 2024, 15:1370676 Int J Mol Sci, 2024, 25(5)2770
S6003	Ataluren (PTC124)	Ataluren (PTC124) selectively induces ribosomal read-through of premature but not normal termination codons, with EC50 of 0.1 μM in HEK293 cells, may provide treatment for genetic disorders caused by nonsense mutations (e.g. CF caused by CFTR nonsense mutation). Phase 3.	Stem Cell Reports, 2022, 17(10):2187-2202 Int J Mol Sci, 2022, 23(7)3541 Biomedicines, 2022, 10(4)886
S7139	CFTRinh-172	CFTRinh-172 (CFTR inhibitor 172) is a voltage-independent, selective CFTR inhibitor with Ki of 300 nM, showing no effects on MDR1, ATP-sensitive K+ channels, or a series of other transporters.	Nat Cancer, 2024, 10.1038/s43018-024-00731-2 Cell Rep, 2023, 42(5):112529 Cells, 2023, 12(23)2741
S8698	GLPG1837	GLPG1837 (ABBV-974) is a novel CFTR potentiator with an EC50 value of 3 nM for F508del, showing enhanced efficacy on CFTR mutants harboring class III mutations compared to Ivacaftor.	iScience, 2022, 25(1):103710 Int J Mol Sci, 2022, 23(18)10758 Front Mol Biosci, 2022, 9:921680
S8795	FDL169	FDL169 is a CFTR corrector that is designed to fix and restore the function of the defective CFTR protein.	Cell Mol Gastroenterol Hepatol, 2021, S2352-345X(21)00158-2 J Pers Med, 2021, 11(7)643 JCI Insight, 2020, 5(18)139983
S8535	Galicaftor (ABBV-2222)	Galicaftor (ABBV-2222, GLPG2222) is a potent corrector of CFTR for the treatment of Cystic Fibrosis (CF).	Biology, 2022, (182)- J Vis Exp, 2022, (182)
S7329	IOWH032	IOWH032 is a synthetic CFTR inhibitor with IC50 of 1.01 μM in CHO-CFTR cell based assays. Phase 2.	Sci Rep, 2023, 13(1):3934
S8094	GlyH-101	GlyH-101 is a selective and reversible CFTR inhibitor with Ki of 4.3 μM.	mBio, 2023, 14(5):e0151623 mBio, 2023, 14(5):e0151623 Cell Mol Immunol, 2020, 10.1038/s41423-020-0499-3
S0198	PPQ-102	PPQ-102 (CFTR Inhibitor IV) is a potent inhibitor of CFTR. PPQ-102 can completely inhibit CFTR chloride current with IC50 of ~90 nM.	Cells, 2023, 12(5)776
E1701New	Vanzacaftor	Vanzacaftor(VX-121) is an orally active corrector of Cystic fibrosis transmembrane conductance regulator (CFTR). Vanzacaftor improves the processing and trafficking of CFTR protein and increases chloride transport in combination with Tezacaftor and Deutivacaftor.
S6911	Nesolicaftor (PTI-428)	Nesolicaftor (PTI-428) is a specific cystic fibrosis transmembrane conductance regulator (CFTR) amplifier that increases CFTR expression.
E1743New	VX-561(CTP-656)	VX-561 (CTP-656), is a potent CFTR modulator and exhibits an EC50 value of 255 nM for CFTR potentiation in G551D/F508del HBE cells.
S6599	KM11060	KM11060 is a small molecule that corrects the processing of cystic fibrosis transmembrane conductance regulator (CFTR) proteins bearing the F508 deletion (F508del) mutation.
S9972	Icenticaftor (QBW251)	Icenticaftor (QBW251, NVP-QBW251) is an oral potentiator of the cystic fibrosis transmembrane conductance regulator (CFTR) channel with EC50 of 79 nM and 497 nM for F508del CFTR and G551D CFTR in Fisher Rat Thyroid (FRT) cells.
S3272	Steviol (Hydroxydehydrostevic acid)	Steviol (Hydroxydehydrostevic acid, Hydroxy Dehydrostevic Acid, NSC 226902), a major metabolite of the sweetening compound stevioside, inhibits CFTR activity, reduces AQP2 expression and promotes AQP2 degradation.
S6003	Ataluren (PTC124)	Ataluren (PTC124) selectively induces ribosomal read-through of premature but not normal termination codons, with EC50 of 0.1 μM in HEK293 cells, may provide treatment for genetic disorders caused by nonsense mutations (e.g. CF caused by CFTR nonsense mutation). Phase 3.	Stem Cell Reports, 2022, 17(10):2187-2202 Int J Mol Sci, 2022, 23(7)3541 Biomedicines, 2022, 10(4)886
S7139	CFTRinh-172	CFTRinh-172 (CFTR inhibitor 172) is a voltage-independent, selective CFTR inhibitor with Ki of 300 nM, showing no effects on MDR1, ATP-sensitive K+ channels, or a series of other transporters.	Nat Cancer, 2024, 10.1038/s43018-024-00731-2 Cell Rep, 2023, 42(5):112529 Cells, 2023, 12(23)2741
S7329	IOWH032	IOWH032 is a synthetic CFTR inhibitor with IC50 of 1.01 μM in CHO-CFTR cell based assays. Phase 2.	Sci Rep, 2023, 13(1):3934
S8094	GlyH-101	GlyH-101 is a selective and reversible CFTR inhibitor with Ki of 4.3 μM.	mBio, 2023, 14(5):e0151623 mBio, 2023, 14(5):e0151623 Cell Mol Immunol, 2020, 10.1038/s41423-020-0499-3
S0198	PPQ-102	PPQ-102 (CFTR Inhibitor IV) is a potent inhibitor of CFTR. PPQ-102 can completely inhibit CFTR chloride current with IC50 of ~90 nM.	Cells, 2023, 12(5)776
S3272	Steviol (Hydroxydehydrostevic acid)	Steviol (Hydroxydehydrostevic acid, Hydroxy Dehydrostevic Acid, NSC 226902), a major metabolite of the sweetening compound stevioside, inhibits CFTR activity, reduces AQP2 expression and promotes AQP2 degradation.
S1144	Ivacaftor (VX-770)	Ivacaftor (VX-770) is a selective potentiator of CFTR targeting G551D-CFTR and F508del-CFTR with EC50 of 100 nM and 25 nM in fisher rat thyroid cells, respectively.	JCI Insight, 2024, 9(15)e174888 Eur J Cell Biol, 2024, 103(2):151416 Int J Mol Sci, 2024, 25(5)2770
S8698	GLPG1837	GLPG1837 (ABBV-974) is a novel CFTR potentiator with an EC50 value of 3 nM for F508del, showing enhanced efficacy on CFTR mutants harboring class III mutations compared to Ivacaftor.	iScience, 2022, 25(1):103710 Int J Mol Sci, 2022, 23(18)10758 Front Mol Biosci, 2022, 9:921680
S6911	Nesolicaftor (PTI-428)	Nesolicaftor (PTI-428) is a specific cystic fibrosis transmembrane conductance regulator (CFTR) amplifier that increases CFTR expression.
S1565	Lumacaftor (VX-809)	Lumacaftor (VX-809, VRT 826809) acts to correct CFTR mutations common in cystic fibrosis by increasing mutant CFTR (F508del-CFTR) maturation,EC50 of 0.1 μM in fisher rat thyroid cells. Phase 3.	Cells, 2024, 13(2)185 Int J Mol Sci, 2024, 25(5)2770 Eur J Pharmacol, 2024, 967:176390
S7059	Tezacaftor (VX-661)	Tezacaftor (VX-661) is a second F508del CFTR corrector and is believed to help CFTR protein reach the cell surface. Phase 2.	Eur J Cell Biol, 2024, 103(2):151416 Front Pharmacol, 2024, 15:1370676 Int J Mol Sci, 2024, 25(5)2770
S8851	Elexacaftor (VX-445)	Elexacaftor (VX-445) is a next-generation cystic fibrosis transmembrane conductance regulator (CFTR) corrector.This is a compound which is not chiral purity.	Eur J Cell Biol, 2024, 103(2):151416 Front Pharmacol, 2024, 15:1370676 Int J Mol Sci, 2024, 25(5)2770
S8795	FDL169	FDL169 is a CFTR corrector that is designed to fix and restore the function of the defective CFTR protein.	Cell Mol Gastroenterol Hepatol, 2021, S2352-345X(21)00158-2 J Pers Med, 2021, 11(7)643 JCI Insight, 2020, 5(18)139983
S8535	Galicaftor (ABBV-2222)	Galicaftor (ABBV-2222, GLPG2222) is a potent corrector of CFTR for the treatment of Cystic Fibrosis (CF).	Biology, 2022, (182)- J Vis Exp, 2022, (182)
E1701New	Vanzacaftor	Vanzacaftor(VX-121) is an orally active corrector of Cystic fibrosis transmembrane conductance regulator (CFTR). Vanzacaftor improves the processing and trafficking of CFTR protein and increases chloride transport in combination with Tezacaftor and Deutivacaftor.
E1743New	VX-561(CTP-656)	VX-561 (CTP-656), is a potent CFTR modulator and exhibits an EC50 value of 255 nM for CFTR potentiation in G551D/F508del HBE cells.
S6599	KM11060	KM11060 is a small molecule that corrects the processing of cystic fibrosis transmembrane conductance regulator (CFTR) proteins bearing the F508 deletion (F508del) mutation.
E1701New	Vanzacaftor	Vanzacaftor(VX-121) is an orally active corrector of Cystic fibrosis transmembrane conductance regulator (CFTR). Vanzacaftor improves the processing and trafficking of CFTR protein and increases chloride transport in combination with Tezacaftor and Deutivacaftor.
E1743New	VX-561(CTP-656)	VX-561 (CTP-656), is a potent CFTR modulator and exhibits an EC50 value of 255 nM for CFTR potentiation in G551D/F508del HBE cells.

CFTRシグナル伝達経路